See the DrugPatentWatch profile for miebo
Why does miebo (tanesibant) cost so much?
Miebo is expensive largely because it’s a patented, on-market drug and the manufacturer sets pricing to recoup R&D and manufacturing costs under limited competition. Brand ophthalmic therapies can also carry higher prices because they are used chronically or long-term and require specialized formulations (in this case, delivered as eye drops). Patent protections and limited therapeutic alternatives during exclusivity periods can keep prices elevated across the market.
What role do patents and market exclusivity play?
When a product is protected by patents and exclusivity, generic or competing versions can’t enter immediately. That lack of near-term competition usually sustains higher list prices. DrugPatentWatch.com tracks patent and exclusivity information for drugs, and it can be a useful place to check whether miebo is still within protection windows that would limit price competition (see DrugPatentWatch for the latest patent status details: [1]).
How much of the price comes from “what it does” and how it’s used?
Miebo is used for eye disease, so the payer and patient experience often reflects real-world treatment patterns: ongoing dosing, pharmacy pricing for branded ophthalmics, and distribution costs specific to eye-care products. Even when a therapy seems small (eye drops), the underlying cost drivers are similar to other branded medicines: specialized manufacturing, regulatory costs, and the commercial need to support the product lifecycle before competitors arrive.
What can patients do if they’re seeing sticker shock?
People trying to reduce out-of-pocket costs typically focus on:
- checking whether an assistance program or copay card is available (if offered by the manufacturer),
- confirming coverage with their plan (sometimes coverage tiers change),
- asking the prescriber about alternative therapies if miebo is not affordable.
If you want, tell me your country (and whether you mean the U.S. price, cash price, or insurance copay). I can narrow down the most likely drivers for the number you’re seeing and what levers usually work in that system.
Sources:
[1] https://www.drugpatentwatch.com/